Document is current
Any future updates will be listed below
-
Authors
,
Ishizaki, Jun http://orcid.org/0000-0001-6287-5011
Takemori, Ayako
Horie, Kenta
Hiraoka, Daisuke
Suemori, Koichiro
Matsumoto, Takuya
Sada, Ken-ei
Amano, Koichi
Harigai, Masayoshi
Arimura, Yoshihiro
Makino, Hirofumi
Takenaka, Katsuto
Takemori, Nobuaki
Hasegawa, Hitoshi
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP17K16209)
Japan Agency for Medical Research and Development (JP17ek0109104, JP20ek0109360)
- License Information
-
More Information
Article History
Received: 29 July 2020
Accepted: 2 March 2021
First Online: 20 March 2021
Declarations
:
: Approval for this study was obtained from the Institutional Review Board of Ehime University Hospital (approval number 1601029, 1609008). Written informed consent was obtained in accordance with the Declaration of Helsinki.
: Not applicable
: MH has received unrestricted research grants from AbbVie Japan GK, Asahi Kasei Co. Medical Ltd., Ayumi Pharmaceutical Co.; Bristol Myers Squibb Co., Ltd.; Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Nippon Kayaku Co., Ltd.; Mitsubishi Tanabe Pharma Co.; Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. MH has received speaker’s fee from AbbVie Japan GK, Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Kissei Pharmaceutical Co., Ltd., Oxford Immuotec, Pfizer Japan Inc., and Teijin Pharma Ltd. HM is a consultant for AbbVie, Boehringer-Ingelheim, and Teijin Pharma. Others have declared that no conflict of interest exists.
